[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiomyopathy-hypertrophic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiomyopathy-hypertrophic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,81,113,137],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100518735","analysis-of-lumbar-spine-stenosis-specimens-for-identification-of-transthyretin-cardiac-amyloidosis-100518735",false,"NCT06034405","Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis","Inclusion Criteria:\n\n1. Clinically indicated spinal decompressive surgery within 20 years prior to enrollment.\n2. Age ≥50 years at the time of the surgery.\n3. Able to understand and sign the informed consent document after the nature of the study has been fully explained.\n\nExclusion Criteria:\n\nThe presence of any of the following excludes eligibility for enrollment in this study:\n\n1. Confirmed primary amyloidosis (AL) or secondary amyloidosis (AA).\n2. Known TTR amyloidosis.\n3. Other reason that would make the subject inappropriate for entry into this study.",true,"ALL","50 Years",{"count":19,"type":20},1663,"ESTIMATED","OBSERVATIONAL","Primary objective:\n\nTo identify older adults with transthyretin cardiac amyloidosis (ATTR-CA) early in the course of the illness, at a time when disease modifying therapies are most effective.\n\nThe specific aims of this epidemiologic investigation include:\n\n1. To identify subjects with previous lumbar spinal stenosis (LSS) Surgery who have evidence of transthyretin (TTR) amyloid deposits in spinal specimens and could be at risk for ATTR cardiac amyloidosis.\n2. To evaluate for ATTR-CA among those with localized TTR in the spinal tissue.\n\nThe study will also explore the following:\n\n1. The prevalence of amyloid in lumbar spinal stenosis specimens by Congo Red staining.\n2. The prevalence of TTR deposits among subjects with amyloid as determined by mass spectrometry.\n3. Evaluation of a novel artificial intelligence technique for that can identify amyloid histologically with standard H\\&E staining.\n4. Difference in ATTR-CA prevalence between subjects with TTR and indeterminate amyloid deposits in subject's spine by myocardial uptake of technetium pyrophosphate scan (Tc99-PYP).",[24,25,26,27,28,29],"Lumbar Spinal Stenosis","Cardiac Amyloidosis","ATTR Amyloidosis Wild Type","ATTR Gene Mutation","ATTRV122I Amyloidosis","Cardiomyopathy, Hypertrophic","RECRUITING","2026-06-02",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2023-09-19",{"date":38,"type":20},"2028-05",{"name":40,"class":41},"Columbia University","OTHER",6,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":21,"phases":4,"briefSummary":53,"conditions":54,"keywords":68,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100558055","national-network-for-cardiovascular-genomics-advancing-cardiovascular-healthcare-for-hereditary-diseases-in-brazils-unified-health-system-through-a-multicenter-registry-100558055","NCT06546137","National Network for Cardiovascular Genomics: Advancing Cardiovascular Healthcare for Hereditary Diseases in Brazil's Unified Health System Through a Multicenter Registry","RENOMICA-Hcor","Inclusion Criteria:\n\n* Clinical diagnosis of a hereditary cardiovascular disease according to current clinical guidelines\n* Agree to receive genetic counseling\n* Sign informed consent form\n* Provide the information required in the case report form\n\nExclusion Criteria:\n\n* Signature absent from informed consent form\n* Inadequate buccal swab (sample may be collected twice)",{"count":51,"type":20},1211,"6 Months","The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:\n\nWhich genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.",[29,55,56,57,58,59,60,61,62,63,64,65,66,67],"Cardiomyopathy, Dilated","Cardiomyopathy Restrictive","Arrhythmogenic Right Ventricular Dysplasia","Non-Compaction Cardiomyopathy","Familial Hypercholesterolemia","Marfan Syndrome","Ehlers-Danlos Syndrome, Vascular Type","Loeys-Dietz Syndrome","Long QT Syndrome","Short Qt Syndrome","Brugada Syndrome","Catecholaminergic Polymorphic Ventricular Tachycardia","Sudden Cardiac Death",[69,70],"hereditary cardiovascular diseases","whole genome sequencing","2026-05-04",{"date":73,"type":34},"2026-05-08",{"date":75,"type":34},"2025-04-30",{"date":77,"type":20},"2026-08-31",{"name":79,"class":41},"Hospital do Coracao",27,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":98,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100598862","mavacamten-enables-exercise-in-hypertrophic-obstructive-cardiomyopathy-100598862","NCT07077005","Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy","MavaEnEx-HOCM: Mavacamten Enables Exercise Training in Patients With Hypertrophic Obstructive CardioMyopathy. A Pilot Study","MavaEnEx","Inclusion Criteria:\n\n* Age ≥18 years of age\n* Diagnosis of hypertrophic obstructive cardiomyopathy\n* ≥12 weeks of unchanged dosage of mavacamten\n* Peak left ventricular outflow tract gradient ≤ 50 mmHg at rest and during stress echocardiography\n* Left ventricular ejection fraction ≥50% at study inclusion\n* New York Heart Association classes I-II\n\nExclusion Criteria:\n\n* Syncope or sustained ventricular tachycardia within 6 months prior to study inclusion\n* Corrected QT-interval (Fridericia-formula) ≥ 500 ms\n* Paroxysmal or intermittent atrial fibrillation (AF) on screening electrocardiogram\n* Persistent or permanent AF without anticoagulation for ≥4 weeks\n* Previous transcoronary ablation of septal hypertrophy or surgical myectomy\n* Ventricular tachycardia, significant ST-elevation or depression upon baseline cardiopulmonary exercise testing\n* ≥ grade II valve insufficiencies or stenoses during resting echocardiography\n* Prior implantable cardioverter defibrillator-implantation\n* Sudden Cardiac Death Risk Score ≥4%","18 Years","99 Years",{"count":92,"type":20},24,"INTERVENTIONAL",[95],"NA","Patients with hypertrophic obstructive cardiomyopathy and New York Heart Association Class I-II under stable treatment with mavacamten (at least 12 weeks without change of dosage) and a peak left ventricular outflow tract obstruction \\\u003C50mmHg undergo either 6 weeks of structured moderate intensity endurance and resistance training (supervised, 3x\u002Fweek, intervention, IT) or usual care (UC). Patients within 1 hour of travel to the training venue will be referred to IT, while those with more than 1 hour will join UC.\n\nAt baseline (visit 1, V1) and after 6 weeks of exercise intervention (visit 2, V2) all patients undergo a medical exam, resting and stress echocardiography and receive a questionnaire on the quality of life (Kansas City Cardiomyopathy Questionnaire). Cardiac biomarkers are assessed. 3 hours after stress echocardiography cardiopulmonary exercise testing is performed to measure peak oxygen consumption (VO2peak).\n\nThe primary outcome is safety. Secondary outcomes include the change of VO2peak, changes in cardiac biomarkers, resting and stress echocardiographic variables, quality of life and variables of cardiopulmonary exercise testing from V1 to V2.",[29],[99,100,101,102],"exercise capacity","mavacamten","safety","exercise training","2025-12-18",{"date":105,"type":34},"2025-12-26",{"date":107,"type":34},"2025-11-01",{"date":109,"type":20},"2027-01-31",{"name":111,"class":41},"Technical University of Munich",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":93,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":112},"100486141","concomitant-hybrid-versus-catheter-ablation-for-atrial-fibrillation-with-hypertrophic-cardiomyopathy-100486141","NCT05610215","Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy","Concomitant Hybrid Versus Catheter Ablation for Reinforcing Therapeutic Effect of Atrial Fibrillation With Hypertrophic Cardiomyopathy","Inclusion Criteria:\n\n1. Patients' age is ≥18 y\n2. Clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm in genetical positive ones-as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging or computed tomography)-that is not explained solely by loading conditions)\n3. Non-obstructed left ventricular outflow obstruction with peak gradients \\\u003C30mmHg\n4. Concomitant with persistent atrial fibrillation (7 days\\\u003Csustained episode lasting\\\u003C3 years) with drug-refractory symptoms.\n5. Be able to understand the contents of the trial, and provide written informed consent to participate in this investigation.\n\nExclusion Criteria:\n\n1. Patients with left atrial size \\>60 mm (2-dimensional echocardiography, parasternal long-axis view)\n2. Contraindicated to systemic anticoagulation\n3. Left ventricular ejection fraction ≤40%\n4. Concomitant with left atrium or left atrial appendage emboli\n5. Concomitant with a coronary or valvular disease that indicates intervention\n6. Ischaemic stroke within 2 months\n7. Previous ablation history\n8. Uncontrolled hyper\u002Fhypothyroidism\n9. End-staged kidney failure\n10. Concomitantly involved in other trials\n11. Pregnant or breastfeeding, or women of childbearing age not using a reliable contraceptive method\n12. Concomitant with bacteremia or at an active phase of infection\n13. Anatomically not suitable for thoracoscopic surgery(history of chest surgery or radiotherapy, etc.)\n14. Unwilling or unable to comply with all peri-ablation and follow-up requirements",{"count":121,"type":20},66,[95],"The goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. The study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.",[125,29,126],"Atrial Fibrillation","Radiofrequency Ablation","2024-08-28",{"date":129,"type":34},"2024-08-30",{"date":131,"type":34},"2023-02-11",{"date":133,"type":20},"2026-12",{"name":135,"class":136},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":112},"100262475","the-chinese-hypertrophic-cardiomyopathy-studychcs-100262475","NCT02696135","The Chinese Hypertrophic Cardiomyopathy Study(CHCS)","CHCS","Inclusion criteria: Patients with HCM diagnosed by observation of unexplained maximal left ventricle wall thickness ≥15 mm on echocardiography and\u002For cardiac magnetic resonance imaging or or ≥13 mm for individuals with family history of HCM.\n\nExclusion criteria: Individuals with other cardiac or systemic diseases capable of producing that magnitude of cardiac hypertrophy.",{"count":145,"type":20},3000,"Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac diseases, with a prevalence of ∼0.2%. Sudden cardiac death (SCD), heart failure and stroke are the major poor outcomes of HCM. Although about half of the patients were found to be caused by mutations mainly located in genes encoding sarcomere proteins, the causes in a significant proportion of patients with HCM are still unknown. Even in the patients with sarcomere mutations, the molecular pathways that eventually lead to cardiac hypertrophy are remained to be revealed. Furthermore, HCM presents with significant heterogeneity. SCD risk stratification and prevention by ICD are necessary. However, the strategy of SCD risk stratification recommended by the 2011 ACCF\u002FAHA and 2014 ESC guidelines were based mainly on the evidence derived from American and European countries. The accuracy of these guidelines in Chines patients with HCM was not evaluated yet.",[29],[149,150,151,152],"hypertrophic cardiomyopathy","clinical outcomes","multi-omics","risk stratification","2018-03-24",{"date":155,"type":34},"2018-03-27",{"date":157,"type":34},"2011-03-23",{"date":159,"type":20},"2028-12-31",{"name":135,"class":136}]